Syntiron is focused on developing innovative vaccines to combat antimicrobial resistance (AMR), particularly through its ALLOY Vaccine Platform. This platform is designed to target multiple bacterial iron receptors, enabling the creation of vaccines that are robust, broadly protective, and easy to manufacture. The first application of this technology is aimed at preventing urinary tract infections (UTIs), which are a significant contributor to global antimicrobial use. By providing a vaccine for UTIs, Syntiron aims to reduce reliance on antibiotics and extend their effectiveness against other infections, addressing a critical need in the fight against AMR.

In addition to UTI vaccines, Syntiron is also working on a maternal vaccine to prevent neonatal sepsis, supported by funding from CARB-X. This initiative highlights the company's commitment to addressing serious health challenges, particularly in low- and middle-income countries where neonatal sepsis is a leading cause of infant mortality. The ALLOY Vaccine Platform's ability to induce multiple arms of immunity and target a wide range of bacterial strains positions Syntiron as a key player in the development of vaccines that can effectively combat AMR and improve global health outcomes.

United States

Syntiron LLC, is dedicated to developing innovative vaccines for humans. Our patented microbial antigen discovery and purification technology targets proteins that acquire iron, a critical nutrient that is required for survival of the bacteria. These proteins are expressed on the cell surface and are similar among different strains, making them ideal vaccine antigens. Our proprietary platform enables rapid identification of these proteins, which can then be directly extracted from the host cell or produced recombinantly for preclinical vaccine development.

Syntiron

Company Details